for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Nova Eye Medical Ltd

EYE.AX

Latest Trade

0.41AUD

Change

0.00(0.00%)

Volume

52,700

Today's Range

0.41

 - 

0.41

52 Week Range

0.29

 - 

0.58

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.41
Open
0.41
Volume
52,700
3M AVG Volume
2.67
Today's High
0.41
Today's Low
0.41
52 Week High
0.58
52 Week Low
0.29
Shares Out (MIL)
143.69
Market Cap (MIL)
59.68
Forward P/E
-21.03
Dividend (Yield %)
--

Next Event

Nova Eye Medical Ltd Annual Shareholders Meeting

Latest Developments

更多

Nova Eye Medical Announces FY21 Trading Update

Nova Eye Medical Announces Filing Of Investigational Device Exemption Application With US FDA

Nova Eye Medical Posts FY Net Profit After Tax A$35.6 Mln

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Nova Eye Medical Ltd

Nova Eye Medical Limited is an Australia-based medical technology company. The Company is focused on developing, manufacturing and selling a portfolio of ophthalmic treatment technologies and devices. Its technologies include iTrack minimally invasive glaucoma surgery (MIGS), which is a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patients' reliance on anti-glaucoma medications for mild-moderate glaucoma. Its Molteno3 glaucoma drainage device platform is designed to manage surgical utility and optimize clinical outcomes for long-term intraocular pressure (IOP) control in cases of severe glaucoma. The Company's 2RT is an ophthalmic laser developed for the therapy of patients in the early to intermediate stages of age-related macular degeneration (AMD).

Industry

Medical Equipment & Supplies

Contact Info

3-4 Second Avenue

ADELAIDE, SA

5095

Australia

+61.8.81045200

http://www.ellex.com/

Executive Leadership

Victor Previn

Executive Chairman of the Board

Mike Southard

Executive Director

Simon Gray

Joint Company Secretary

Tom Spurling

Director

Alexander M. Sundich

Non-Executive Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, AUD)

2019

0.1K

2020

0.0K

2021

0.0K

2022(E)

0.0K
EPS (AUD)

2019

-0.040

2021

-0.030

2022(E)

-0.020
Price To Earnings (TTM)
--
Price To Sales (TTM)
4.38
Price To Book (MRQ)
1.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
10.47
LT Debt To Equity (MRQ)
4.98
Return on Investment (TTM)
-6.24
Return on Equity (TTM)
-5.49

Latest News

Latest News

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up